Ana Paula Tagliari, Cardiac Surgeon, Professor at Federal University of Rio Grande do Sul – UFRGS, shared on X:
“One of the most anticipated trials at TCT2026 is being presented by Philippe Genereux.
PROGRESS Trial: TAVR vs. clinical surveillance in patients with moderate AS and at-risk features. At 2 years, TAVR reduced death or HF events (16.7% vs. 23.9%; HR 0.67, p=0.02), driven by fewer HF events.
Will this trial change how we manage moderate AS? ”
TCT 2026 was a major medical conference focused on interventional cardiovascular medicine and breakthrough heart treatments. Organized by the Cardiovascular Research Foundation (CRF), the event brought together global specialists to share cutting-edge scientific discoveries and practice-changing clinical data.
The core of the conference focused on several critical medical advancements:
- Late-Breaking Clinical Trials: Presentations of highly anticipated scientific studies that establish new data, guidelines, and safety standards for treating heart diseases.
- Transcatheter and Structural Heart Interventions: Insights into minimally invasive procedures for treating heart valve diseases, coronary conditions, and structural heart defects without open-heart surgery.
- Medical Innovation & Artificial Intelligence: Expert sessions on how data-driven tools and AI are being integrated into cardiology to improve patient diagnosis, imaging, and treatment planning.
- Live Case Transmissions: Broadcasts of complex surgeries performed by leading specialists, showcasing real-time techniques and the practical application of novel medical devices.
You can also read more articles on Oncolibrary.
